Ensign Peak Advisors, Inc Kura Oncology, Inc. Transaction History

Ensign Peak Advisors, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$7.58 - $14.38 $339,477 - $644,022	-44,786 Reduced 38.43%	71,742 $1.03 Million
Q4 2022 Feb 13, 2023	BUY	$11.23 - $16.9 $132,244 - $199,014	11,776 Added 11.24%	116,528 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $353,406 - $572,335	29,426 Added 39.06%	104,752 $1.43 Million
Q2 2022 Aug 12, 2022	BUY	$10.71 - $18.33 $743,766 - $1.27 Million	69,446 Added 1181.05%	75,326 $1.38 Million
Q4 2021 Feb 11, 2022	BUY	$12.22 - $19.57 $71,853 - $115,071	5,880 New	5,880 $82,000
Q2 2021 Aug 13, 2021	SELL	$20.85 - $29.88 $736,818 - $1.06 Million	-35,339 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$29.0 - $41.62 $207,350 - $297,583	-7,150 Reduced 16.83%	35,339 $1.15 Million
Q3 2020 Nov 12, 2020	BUY	$16.3 - $30.64 $692,570 - $1.3 Million	42,489 New	42,489 $1.3 Million
Q2 2020 Aug 12, 2020	SELL	$7.95 - $18.81 $52,843 - $125,030	-6,647 Closed	0 $0
Q1 2020 May 11, 2020	SELL	$6.45 - $14.04 $42,873 - $93,323	-6,647 Reduced 50.0%	6,647 $66,000
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $172,423 - $211,906	13,294 New	13,294 $183,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.